Applications

1832 – Detection of measurable residual disease (MRD) in patients with multiple myeloma (MM)

Find out about the service or technology in application 1832 and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input, and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type New application
  • Pre-PASC consultation Open
  • Pre-MSAC consultation Not yet started
  • Outcome Pending

Application details

Applicant

Adaptive Biotechnologies Corporation

Reason for application

New Medicare Benefits Schedule item

Service or technology in this application

Measurable residual disease (MRD) testing uses highly sensitive laboratory methods to look for very small numbers of myeloma cancer cells that remain after treatment. These amounts may be too low to see under a microscope. The main test methods used are flow cytometry, which identifies cells by their features, and molecular methods like next-generation sequencing (NGS), which checks genetic material. Doctors can use the results to see how well treatment has worked and estimate the risk that multiple myeloma will return. This may help them decide whether a person needs more or less intensive treatment.

Medical condition this application addresses

Multiple myeloma is an aggressive cancer that starts in the bone marrow, where blood cells are made. It causes plasma cells, a type of white blood cell that helps fight infection, to develop abnormally. These cancer cells build up in the bone marrow and crowd out healthy cells, reducing the body's ability to make normal blood cells. Symptoms can include bone pain, repeated infections, tiredness and signs of kidney disease. Multiple myeloma often returns after treatment.

Consultation survey and deadlines

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the application is addressing.   

Before providing your input, please read our Privacy Notice for MSAC consultation input to ensure you are comfortable with how we will use your input.  

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: Friday 6 November 2026 11:59 pm AEDT
  • Pre-MSAC consultation deadline: To be confirmed

For other ways to provide input, see how to have your say.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: 10 to 11 December 2026
  • ESC meeting: To be confirmed
  • MSAC meeting: To be confirmed

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: